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To the Editor: Many patients in South Africa develop profound
visual loss every year as a result of chloroquine toxicity. The
patients are often oblivious of the toxic effects of the drug and
have been given higher-than-recommended doses, very often
due to the ignorance of prescribing doctors. These patients
have not been sent for ocular testing. There is no means of
reversing the drug’s blinding effect.
Hydroxychloroquine (Plaquenil) is much safer than
chloroquine, with a lower risk of retinal damage (maximum
dose 400 mg/day or 6.5 mg/kg/day). It is currently available
on motivation on a named patient basis from Sanofi Synthelabo
(tel. (011) 319-8656), and should always be used instead of
chloroquine.
Chloroquine-related blindness has been almost completely
eradicated in Western countries where hydroxychloroquine is
freely available.
Maculopathy is a much less frequent occurrence and is
much less severe if hydroxychloroquine is used rather than
chloroquine.1
Chloroquine (Nivaquine, Daramal, Plasmoquine) is an
antimalarial first used during World War II. It is prescribed for
treatment of amoebiasis, rheumatoid arthritis, juvenile chronic
arthritis, systemic lupus erythematosus and discoid lupus and
as prophylaxis against malaria.
The drug is excreted very slowly from the body and
becomes concentrated in the melanin-containing cells of the
retinal pigment epithelium (RPE) and choroid.
Retinal toxicity with degeneration of the RPE and
neurosensory retina occur and are a severe sight-threatening
complication of chloroquine use.
Most cases of toxicity have developed when a higher-than-
recommended dose is used: 200 mg/day or 3.5 mg/kg/day
(using lean body weight). A total cumulative dose between 100
and 300 g is usually required to cause toxicity, i.e. 200 mg/day
for 3 years.
The earliest visual manifestation of retinal toxicity is a
paracentral scotoma. This occurs before visual acuity loss or
ophthalmoscopic fundus changes. If the drug is discontinued
the scotoma usually disappears.
By the time a characteristic bull’s eye maculopathy occurs
there is moderate visual acuity loss (6/18 - 6/12), with an area
of depigmentation around the fovea surrounded by a ring of
hypopigmentation. This enlarges slowly. This stage of
retinopathy may progress even if the drug is stopped, and
indicates irreversible damage.2
Eventually there is end-stage maculopathy with severe
visual acuity loss and marked atrophy of the RPE of the entire
retina with unmasking of the choroidal vessels as well as
secondary damage to the neurosensory retina. Retinal arteries
become attenuated, the optic disc is pale and pigment clumps
develop in the peripheral retina (pseudo-retinitis pigmentosa).
Screening is mandatory for all patients on chloroquine
therapy:3 (i) baseline examination by an ophthalmologist within
6 months of starting treatment; (ii) annual screening for the
first 5 years after starting treatment if patients are taking
higher-than-recommended doses and are at higher risk due to
age over 60 years, or associated renal/liver or retinal disease;
and (iii) 2-yearly for other low-risk users of chloroquine.
Fluorescein angiography is also helpful in early
demonstration of RPE abnormalities before vision loss occurs.
Prevention is the best form of treatment.
Strict adherence to drug dosages is imperative. The
chloroquine daily dose is thought to be more important than
the cumulative dose and should be tailored according to
gender and height (Table I).
Pressure by rheumatologists, dermatologists and
ophthalmologists to get hydroxychloroquine registered in
South Africa is critical. We encourage all prescribing doctors in
South Africa to switch their patients to hydroxychloroquine.4
This will bring us in line with other countries where
chloroquine-induced blindness has been virtually eliminated.
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Chloroquine-induced retinal toxicity
Table I. Recommended daily chloroquine dosage
Females Males
Height (cm) Tablets/week Height (cm) Tablets/week
< 146 4 < 150 5
146 - 156 5 150 - 160 6
158 - 172 6 > 162 7
> 172 7
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